DUBLIN, Dec. 14, 2023 /PRNewswire/ — The “Adalimumab (Humira) Biosimilars Pipeline Review” report has been added to ResearchAndMarkets.com’s offering.
This product provides basic information on approved drugs and drug candidates in research and development as biosimilar antibodies of Humira (adalimumab).
Adalimumab (drug code: LU-200134) was discovered by Knoll Pharmaceuticals, a subsidiary of BASF, using phage display technology from Cambridge Antibody Technology (CAT, acquired by AstraZeneca). In 2001, Abbott acquired Knoll Pharmaceuticals for US$ 6.9 bln, and continued clinical development of adalimumab (drug code: ABT-D2E7) until first approval in 2022 and subsequent approvals in various indications and for different formulations and presentation forms. Since its launch in 2003 for rheumatoid arthritis, Humira annual sales exceeded $1 billion in 2005 for the first time, and exceeded $2 billion in annual sales in 2006.
In January 2013, Abbott completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. Humira generated cumulative worldwide (ex Japan) sales for Abbott/AbbVie of more than US$ 213 bln. Eisai holds commercialization rights for Humira in Japan.
Adalimumab is a recombinant human IgG1 monoclonal antibody created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgG1:k constant regions. Adalimumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary (CHO)) expression system and is purified by a process that includes specific viral inactivation and removal steps. It consists of 1330 amino acids and has a molecular weight of approximately 148 kilodaltons.
Humira’s main patents expired in 2016 and first biosimilar versions of Humira were launched in Europe in 2018. AbbVie filed about 250 patent applications for Humira in the U.S., 90% of them following the drug’s 2002 approval. The strengthened patent shield has stretched AbbVie’s legal monopoly in the U.S. for six years beyond the expiration of Humira’s main patent in 2016.
Amgen was the first to launch its Humira biosimilar in the US in January 2023, and more entries of Humira biosimilars into the US market are scheduled over the course of 2023, mainly in July.
Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product.
In the US, Humira is approved for treatment of
- Moderate to severe rheumatoid arthritis (RA) in adults;
- Moderate to severe polyarticular juvenile idiopathic arthritis (JIA) in children 2 years of age and older;
- Psoriatic arthritis (PsA) in adults;
- Ankylosing spondylitis (AS) in adults;
- Moderate to severe hidradenitis suppurativa (HS) in people 12 years and older;
- Moderate to severe Crohn’s disease (CD) in adults and children 6 years of age and older;
- Moderate to severe ulcerative colitis (UC) in adults and children 5 years of age and older;
- Moderate to severe chronic plaque psoriasis (Ps) in adults; and
- Non-infectious intermediate, posterior, and panuveitis in adults and children 2 years of age and older.
This product consists of:
- Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, territory of main competitor, indication(s) & R&D stage, including published sales data.
- Project History with link to source of information (press release, homepage, abstracts, presentations, annual reports etc).
- One-month online access to the publisher’s database for adalimumab biosimilars (prerequisite: access to internet).
For more information about this report visit https://www.researchandmarkets.com/r/yqjxx7
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
